Viagra’s End Begins: Generic Sildenafil Launches For Revatio
This article was originally published in The Pink Sheet Daily
Executive Summary
Apotex has launched sildenafil for treatment of pulmonary arterial hypertension; its product is bioequivalent to Revatio, Pfizer’s sildenafil formulation for PAH, not Viagra; FDA also approved Watson, Dr. Reddy’s and Torrent sildenafil ANDAs.
You may also be interested in...
Teva’s Generic Viagra Launch Will Be Offset By Generic Cialis
Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.
Actelion And Bayer Hope Novel Drugs Can Take Over The Pulmonary Hypertension Market
Impressive Phase III trial data on Actelion’s macitentan and Bayer’s riociguat generated big noises at the annual meeting of the American College of Chest Physicians in Atlanta and should support regulatory filings for the two therapies.
Viagra Patent Ruling Could Deter Appeal, Support Pfizer Position In Pending Cases
Teva Pharmaceuticals USA Inc. is considering whether to appeal a federal court decision upholding the validity of Pfizer Inc.'s Viagra (sildenafil) patent.